共 8 条
[1]
Phase I–IIa study of BMS-690514; an EGFR; HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor; in patients with advanced or metastatic solid tumours.[J].Jean-Charles Soria;José Baselga;Nasser Hanna;Scott A. Laurie;Rastislav Bahleda;Enriqueta Felip;Emiliano Calvo;Jean-Pierre Armand;Frances A. Shepherd;Christopher T. Harbison;David Berman;Jong-Soon Park;Steven Zhang;Blisse Vakkalagadda;John F. Kurland;Ashutosh K. Pathak;Roy S. Herbst.European Journal of Cancer.2013, 8
[2]
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.[J].Mark Agulnik;Johnson;Ziehr;Nelson.OncoTargets and Therapy.2013, defa
[3]
Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions
[J].
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY,
2012, 84 (01)
:47-58
Ellis, Peter M.
;
Al-Saleh, Khalid
.
[4]
EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment.[J].Wolfram Brugger;Michael Thomas.Lung Cancer.2011, 1
[5]
DNA Damage-Mediated Induction of a Chemoresistant Niche
[J].
CELL,
2010, 143 (03)
:355-366
Gilbert, Luke A.
;
Hemann, Michael T.
.
[6]
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.[J].Michael J. Eck;Cai-Hong Yun.BBA - Proteins and Proteomics.2009, 3
[7]
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
[J].
PLOS MEDICINE,
2005, 2 (03)
:225-235
Pao, W
;
Miller, VA
;
Politi, KA
;
Riely, GJ
;
Somwar, R
;
Zakowski, MF
;
Kris, MG
;
Varmus, H
.
[8]
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling..Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song;Courtney Hyl;Joon Oh Park;Neal Lindeman;Christopher-Michael Gale;Xiaojun Zhao;James Christensen;Takayuki Kosaka;Alison J. Holmes;Andrew M. Rogers;Federico Cappuzzo;Tony Mok;Charles Lee;Bruce E. Johnson;Lewis C. Cantley;Pasi A. Jn;.Science.2007, 316